Rafael de la Espriella-Juan

List of Publications by Year
in descending order

56 papers	855 citations	586496 16 h-index	620720 26 g-index
56 all docs	56 docs citations	56 times ranked	812 citing authors

#	Article	IF	Citations
1	Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia. Nephrology Dialysis Transplantation, 2022, 37, 522-530.	0.4	5
2	Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. European Journal of Internal Medicine, 2022, 95, 67-73.	1.0	10
3	Hospitalization following an emergency-department visit for worsening heart failure: The role of left ventricular ejection fraction. Medicina ClÃnica, 2022, 159, 157-163.	0.3	1
4	Sexâ€Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum. Journal of the American Heart Association, 2022, 11, e022404.	1.6	7
5	Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction. Scientific Reports, 2022, 12, 1344.	1.6	7
6	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure. CKJ: Clinical Kidney Journal, 2022, 15, 865-872.	1.4	16
7	OUP accepted manuscript. European Heart Journal: Acute Cardiovascular Care, 2022, , .	0.4	5
8	Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators. Frontiers in Cardiovascular Medicine, 2022, 9, 836451.	1.1	3
9	Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis. Journal of Clinical Medicine, 2022, 11, 2559.	1.0	0
10	Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Failure, 2022, 9, 2170-2180.	1.4	17
11	Shortâ€term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (<scp>DAPAâ€VO₂</scp>): a randomized clinical trial. European Journal of Heart Failure, 2022, 24, 1816-1826.	2.9	22
12	Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction. Revista Espanola De Cardiologia (English Ed), 2021, 74, 616-623.	0.4	4
13	Soluble ST2 and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction. Journal of Cardiac Failure, 2021, 27, 427-434.	0.7	9
14	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.4	3
15	Iron deficiency and short-term adverse events in patients with decompensated heart failure. Clinical Research in Cardiology, 2021, 110, 1292-1298.	1.5	9
16	CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 475-483.	0.4	18
17	ComparaciÃ³n entre CA125 y NT-proBNP para valorar la congestiÃ³n en insuficiencia cardÃaca aguda. Medicina ClÃnica, 2021, 156, 589-594.	0.3	18
18	Right Heart Dysfunction and Readmission Risk Across Left Ventricular Ejection Fraction Status in Patients With Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 1090-1098.	0.7	3

#	Article	IF	Citations
19	Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. European Journal of Heart Failure, 2021, 23, 1445-1457.	2.9	60
20	Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure. International Journal of Cardiology, 2021, 339, 102-105.	0.8	11
21	Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure. European Journal of Internal Medicine, 2021, 92, 94-99.	1.0	4
22	Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study. ESC Heart Failure, 2021, 8, 4685-4692.	1.4	20
23	Right ventricular function and iron deficiency in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 406-414.	0.4	8
24	Effect of Î²-Blocker Withdrawal on Functional Capacity in HeartÂFailure and Preserved Ejection Fraction. Journal of the American College of Cardiology, 2021, 78, 2042-2056.	1.2	97
25	Differential prognostic impact of type 2 diabetes mellitus in women and men with heart failure with preserved ejection fraction. Revista Espanola De Cardiologia (English Ed), 2020, 73, 463-470.	0.4	12
26	CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. American Journal of Medicine, 2020, 133, 370-380.e4.	0.6	58
27	Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: Let's leave the doubts behind. International Journal of Cardiology, 2020, 300, 198-200.	0.8	0
28	Lipoprotein(a) and long-term recurrent infarction after an episode of ST-segment elevation acute myocardial infarction. Coronary Artery Disease, 2020, 31, 378-384.	0.3	3
29	Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure. ESC Heart Failure, 2020, 7, 3320-3328.	1.4	2
30	Early Spot Urinary Sodium and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction. CardioRenal Medicine, 2020, 10, 362-372.	0.7	5
31	Renal function dynamics following coâ€administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes. ESC Heart Failure, 2020, 7, 3792-3800.	1.4	11
32	Ejection Fraction by Echocardiography for a Selective Use of Magnetic Resonance After Infarction. Circulation: Cardiovascular Imaging, 2020, 13, e011491.	1.3	12
33	Clinical profile and 1-year clinical outcomes of super elderly patients admitted with acute heart failure. European Journal of Internal Medicine, 2020, 81, 78-82.	1.0	5
34	Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 831.	1.0	15
35	CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. International Journal of Cardiology, 2020, 308, 54-59.	0.8	28
36	Rehospitalization burden and morbidity risk in patients with heart failure with midâ€range ejection fraction. ESC Heart Failure, 2020, 7, 1007-1014.	1.4	14

#	Article	IF	Citations
37	Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 437-447.	0.4	32
38	Urine: an overlooked biomedium in heart failure?. Biomarkers in Medicine, 2020, 14, 165-168.	0.6	1
39	Betaâ€blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserveâ€HR trial). Clinical Cardiology, 2020, 43, 423-429.	0.7	18
40	Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardialâ€IRON Trial. Journal of the American Heart Association, 2020, 9, e014254.	1.6	58
41	Usefulness of Right Ventricular to Pulmonary Circulation Coupling as an Indicator of Risk for Recurrent Admissions in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2019, 124, 567-572.	0.7	38
42	Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. International Journal of Cardiology, 2019, 291, 83-88.	0.8	16
43	Changes in myocardial iron content following administration of intravenous iron (Myocardialâ€IRON): Study design. Clinical Cardiology, 2018, 41, 729-735.	0.7	15
44	Carbohydrate Antigen-125 in Heart Failure. JACC: Heart Failure, 2018, 6, 441-442.	1.9	5
45	Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?. Cardiovascular Diagnosis and Therapy, 2018, 8, 549-551.	0.7	0
46	Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness. ESC Heart Failure, 2018, 5, 1173-1175.	1.4	22
47	Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia, 2018, 10, e011044.	1.1	26
48	Use of acetazolamide in the treatment of patients with refractory congestive heart failure. Cardiovascular Therapeutics, 2018, 36, e12465.	1.1	13
49	Coronary sinus atrial septal defect in a 65-year-old woman: Diagnosis by two- and three-dimensional echocardiography. Revista Portuguesa De Cardiologia, 2017, 36, 67-68.	0.2	1
50	Echocardiographic pulmonary artery pressure estimation and heart failure rehospitalization burden in patients with acute heart failure. International Journal of Cardiology, 2017, 241, 407-410.	0.8	20
51	Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1067-1073.	0.4	5
52	Functional Mitral Regurgitation Predicts Short-Term Adverse Events in Patients With Acute Heart Failure and Reduced Left Ventricular Ejection Fraction. American Journal of Cardiology, 2017, 120, 1344-1348.	0.7	20
53	Red blood cell distribution width and erythrocyte deformability in patients with acute myocardial infarction. Clinical Hemorheology and Microcirculation, 2015, 59, 107-114.	0.9	25
54	Isolated RV diverticulum: diagnosis by cardiac magnetic resonance and 3D TEE. European Heart Journal Cardiovascular Imaging, 2015, 16, 114-114.	0.5	0

#	Article	IF	Citations
55	Prognostic value of pulmonary vascular resistance estimated by cardiac magnetic resonance in patients with chronic heart failure. European Heart Journal Cardiovascular Imaging, 2014, 15, 1391-1399.	0.5	16
56	Giant pulmonary mass complicating pulmonary homograft replacement. European Heart Journal Cardiovascular Imaging, 2014, 15, 248-248.	0.5	2